Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. - Wikidata - wikimedia - TriplyDB

Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.

Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.

http://www.wikidata.org/entity/Q44415307

about

Neuropeptides and their receptors: innovative science providing novel therapeutic targets Evolving treatment paradigms for chemotherapy-induced nausea and vomiting Difference in the emetic control among highly emetogenic chemotherapy regimens: Implementation for appropriate use of aprepitant Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program.Toxicities of the platinum antineoplastic agents.The Role of Supportive Therapy in the Era of Modern Adjuvant Treatment - Current and Future Tools.Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting.Review article: current and emerging therapies for functional dyspepsia.Treating irritable bowel syndrome: overview, perspective and future therapies.Behavioral patterns associated with chemotherapy-induced emesis: a potential signature for nausea in musk shrews.Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients.Granisetron: new insights into its use for the treatment of chemotherapy-induced nausea and vomiting.Aprepitant and fosaprepitant: a 10-year review of efficacy and safety Nausea and vomiting associated with cancer chemotherapy: drug management in theory and in practice Aprepitant--a novel NK1-receptor antagonist.Quality of life in patients receiving treatment for gynecologic malignancies: special considerations for patient care.Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis: summary of clinical trials.Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparison Employment of substandard antiemetic prophylaxis in recent trials of chemotherapy-induced nausea and vomiting.Aprepitant (EMEND): the role of substance P in nausea and vomiting.Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature Clinical practice guidelines on antiemetics in oncology.Emerging drugs for chemotherapy-induced emesis.Emerging drugs for irritable bowel syndrome.Review article: modulation of the brain-gut axis as a therapeutic approach in gastrointestinal disease.Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant Preparation and Characterization of Nanosuspension of Aprepitant by H96 Process.Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting.Novel therapeutic approaches in IBS.Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.Pathophysiological and neurochemical mechanisms of postoperative nausea and vomiting Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant.Combination of Aprepitant, Azasetron, and Dexamethasone as Antiemetic Prophylaxis in Women with Gynecologic Cancers Receiving Paclitaxel/Carboplatin Therapy.Aprepitant: drug-drug interactions in perspective.Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy.Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting.Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.

P2860

Q24670220-1CDC7851-D279-4A62-A101-333CAC3902DE Q27024463-476770A9-B1E3-4213-8997-F156165E3942 Q28236344-F358FAD2-1A59-4D23-8361-944F59D3DABA Q28258863-CA2D54ED-DA57-4097-A84D-BEC48BB6D7A4 Q31061449-B6DDC06E-AC1F-4BC0-84B7-BD672C052CF3 Q33357351-4A1B73E1-1874-4C02-88FA-41D981BB1107 Q34095827-93F9C510-9E21-4D41-A744-1A71D24CDAEA Q34450534-740648CD-F780-4AFA-942F-D99F7647BC51 Q34553942-59859B33-68A9-4338-B96D-C5A5ECE2315C Q35047051-6DD4035A-03F6-4813-AEF3-891550B70403 Q35114037-847A427B-BDB3-4E00-9D01-86BF6E890EB8 Q35182204-C5655B25-4A33-41C4-9E26-BCA472D82CA1 Q35207599-EF67EE2D-64ED-4B3D-9638-5D0C49B3F277 Q35345557-2F158568-5EA3-413A-B0CC-0529D4D74F75 Q35571607-1C339552-5BE4-4091-80B5-5241B2352795 Q35594000-AE329757-AA07-41DC-B523-2F7337A0BCD6 Q35648863-4E8D7E00-E552-41BA-B72C-35664B3A4871 Q35779340-AB28AB7F-2E93-4D4C-90AB-58CF5D26D9DA Q35918427-F06AEF70-12A5-46A6-899F-C78DA02CF9B5 Q35964412-D22FCA21-F4F3-4DEE-94BD-6FDA96F50A3D Q35970506-E0B4786F-8EBC-41CC-88C6-E0264A6FC828 Q36276557-D6B60649-BF84-4FBB-903F-75F1FA15B3DF Q36284018-CAED1E2E-AD09-4929-A3AE-A47A580394C7 Q36311246-C9499AF0-BA50-44FE-A5B0-446D6B1624B5 Q36334870-B7668A0D-2DAC-43B3-80AB-6225AC4EA553 Q36407422-C4971A9F-EBEE-4BB4-BCAD-6EC70B62160B Q36458417-28D516FD-6588-4EBC-82B7-E00618C7A594 Q36583822-27AB9625-9D79-4038-AD46-C382026610E5 Q36823546-323E0717-1E8F-4792-B7CB-7DDF989614B2 Q36837167-3063685A-7628-4FA9-9FBE-91185403A48F Q36843470-0D897F24-E2A5-4A03-B61F-D9837505A155 Q37002201-C2D5297A-0442-465E-9881-AE0A1BF08174 Q37316977-DB7D9D1C-E608-4BDD-A5FE-C645A92C885C Q37559641-29EAB59C-DA1F-4A31-90EC-4DEE7EDE3709 Q37636064-8F02BBFF-D76F-43B8-95DE-DCF7BA9957BE Q37661865-217D291E-9E71-455D-BD0E-E58248360DF8 Q37757799-A7C8A471-C050-4050-A8D8-5D5E9B9EECFD Q37783929-FD08596B-2572-4E14-B83F-CDD463F7B9BF Q37854702-7B09AFCB-9576-4C88-8F4F-B60043A7FF9C Q37857329-784DC9B9-D5BA-4B69-A9A2-88F646524C81

P2860

Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.

http://www.wikidata.org/entity/Q44415307

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Establishing the dose of the o ...... y-induced nausea and vomiting.

@en

Establishing the dose of the o ...... y-induced nausea and vomiting.

@nl

type

label

Establishing the dose of the o ...... y-induced nausea and vomiting.

@en

Establishing the dose of the o ...... y-induced nausea and vomiting.

@nl

prefLabel

Establishing the dose of the o ...... y-induced nausea and vomiting.

@en

Establishing the dose of the o ...... y-induced nausea and vomiting.

@nl

P1433

Q44415307-93016E05-B93C-4C78-9323-816A524802AF

P1476

Q44415307-54B8EA75-AA2C-4094-AB56-7C3FC98B4E34

P2093

Q44415307-075B1250-58A4-4C31-8E17-BB0D4718C527

Q44415307-0F98204A-3BDF-4983-8B6F-01FE59B7FB47

Q44415307-3806BAB3-79FB-49C6-9FCB-E322BBB04D4C

Q44415307-55926832-FB99-45D0-86BA-3586BDCE9C39

Q44415307-6EB02EC7-4204-40C0-ACE3-CA18CFB8D583

Q44415307-790684CF-2CA0-40F8-B4DA-9283C5D84939

Q44415307-804534BF-3B16-44DF-96B6-2BB8385E136A

Q44415307-AFB1A89C-7762-4CB3-B5DE-D7AF844AFCF1

Q44415307-CE6D52EE-CD5D-4D66-81EA-26FFD27C659D

Q44415307-F3F89908-0BAA-4225-BDEC-95ED91426C7B

P2860

Q44415307-1096A5AB-4647-4CD0-94F7-69BF094839B7

Q44415307-10F5B217-0E36-40BA-8233-582E78CA5E31

Q44415307-300E6854-8FDF-4025-ACED-3941D9E1A060

Q44415307-6FD23F8E-5BD9-4F27-950A-EDA4517DE55F

Q44415307-FFA42524-628E-4153-B2E3-A85624406C9E

P304

Q44415307-E1E3A227-7C46-4B4D-ABFD-F6EE201E1BE4

P31

Q44415307-8A1248F1-5234-4B3A-913F-25AE3F8432F1

P356

Q44415307-2CA1CA4A-026B-44A6-BAE7-676696B59659

P407

Q44415307-8EBC90E9-26FA-463D-BAE1-37D9E65AA7CE

P433

Q44415307-103F9A59-6776-40BC-85A9-FB08CFDE9FA3

P478

Q44415307-DC8E8BC6-5606-4288-A8D0-B51135D5AF42

P50

Q44415307-C167F4DB-430C-4F49-8E7B-36977F3E8CEF

P577

Q44415307-BB582EA8-C899-4BF6-9C0E-2027327A30B8

P5875

Q44415307-A810C478-B48C-4DED-B791-E19025980C0A

P698

Q44415307-7BC0EECD-A7E5-428D-9F6E-B5A57B4DF1B6

P921

Q44415307-EE08A33B-CBF4-40A7-97E1-772305664F3D

P356

P1433

P1476

Establishing the dose of the o ...... py-induced nausea and vomiting

@en

P2093

Alexandra D Carides

http://www.w3.org/2001/XMLSchema#string

Arlene Taylor

http://www.w3.org/2001/XMLSchema#string

Carrie Schmidt

http://www.w3.org/2001/XMLSchema#string

Cindy Rittenberg

http://www.w3.org/2001/XMLSchema#string

Judith K Evans

http://www.w3.org/2001/XMLSchema#string

Mary E Elmer

http://www.w3.org/2001/XMLSchema#string

Paul J Hesketh

http://www.w3.org/2001/XMLSchema#string

Richard J Gralla

http://www.w3.org/2001/XMLSchema#string

Sant P Chawla

http://www.w3.org/2001/XMLSchema#string

Steven M Grunberg

http://www.w3.org/2001/XMLSchema#string

P2860

The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK1 receptor.

Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists.

On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993.

Stevens-Johnson syndrome, respiratory distress and acute renal failure due to synergic bleomycin-cisplatin toxicity.

A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group.

P304

2290-2300

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.11320

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

97

http://www.w3.org/2001/XMLSchema#string

P50

P577

2003-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10788684

http://www.w3.org/2001/XMLSchema#string

P698

12712486

http://www.w3.org/2001/XMLSchema#string

P921